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Determination of hormone receptor (estrogen receptor and progesterone receptor) and human epidermal growth
factor receptor 2 status in the primary tumor is clinically relevant to define breast cancer subtypes, clinical outcome,
and the choice of therapy. Retrospective and prospective studies suggest that there is substantial discordance in
receptor status between primary and recurrent breast cancer. Despite this evidence and current recommendations,
the acquisition of tissue from metastatic deposits is not routine practice. As a consequence, therapeutic decisions
for treatment in the metastatic setting are based on the features of the primary tumor. Reasons for this attitude
include the invasiveness of the procedure and the unreliable outcome of biopsy, in particular for biopsies of lesions
at complex visceral sites. Improvements in interventional radiology techniques mean that most metastatic sites are
now accessible by minimally invasive methods, including surgery. In our opinion, since biopsies are diagnostic and
changes in biological features between the primary and secondary tumors can occur, the routine biopsy of
metastatic disease needs to be performed. In this review, we discuss the rationale for biopsy of suspected breast
cancer metastases, review issues and caveats surrounding discordance of biomarker status between primary and
metastatic tumors, and provide insights for deciding when to perform biopsy of suspected metastases and which
one (s) to biopsy. We also speculate on the future translational implications for biopsy of suspected metastatic
lesions in the context of clinical trials and the establishment of bio-banks of biopsy material taken from metastatic
sites. We believe that such bio-banks will be important for exploring mechanisms of metastasis. In the future,
advances in targeted therapy will depend on the availability of metastatic tissue.Introduction
Confirmatory biopsy of breast cancer metastases may have
many potential benefits: confirming metastatic disease;
disclosing non-malignant disease or other primary tumors;
and confirming concordance (or discordance) of biological
features of disease such as estrogen receptor (ER), proges-
terone receptor (PgR) and human epidermal growth factor
receptor (HER)2 status. Any one of these may contribute
to the optimal management of patients with metastatic
breast cancer. Discordance in ER, PgR and HER2 status
between primary and metastatic breast cancer has been
frequently reported [1]. Although evidence for this has* Correspondence: giuseppe.curigliano@ieo.it
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recent studies have prospectively evaluated the impact of
phenotype discordance in patient management (for ex-
ample, treatment planning) and survival [2]. Re-evaluating
the biological features of disease using metastatic lesions
has been largely individualized, although recent practice
guidelines of the National Comprehensive Cancer Network
recommend biopsy of metastatic sites, especially when they
represent the first recurrence of disease and/or ER/PgR/
HER2 status is unknown or was originally negative. How-
ever, the acquisition of tissue from suspected breast cancer
metastases is not always performed in routine practice.
Therefore, therapeutic decisions in the metastatic setting
are often based on the features of the primary tumor. This
often adopted attitude in routine clinical practice is contrary
to increasing evidence on the extent and prevalence ofral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
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nologies, which have provided insight into the remarkable
genetic complexity of cancers [3]. Intra-tumor heterogeneity
refers to the existence of subpopulations of cells within a
primary tumor and its metastases that have distinct geno-
types and phenotypes and may have different biological
behaviors [3]. Intra-tumor heterogeneity has implications for
cancer therapeutics and biomarker discovery, particularly in
the era of personalized medicine, thus ultimately impacting
on clinical outcome. In order to better understand the
processes that cause intra-tumor heterogeneity and improve
patient care and clinical outcomes, clinical trials including
comprehensive tissue collection protocols are warranted.
Potential benefits and rationale for biopsying
metastatic sites
Biopsies of breast cancer metastases have many potential
benefits. Primarily, biopsying the metastatic site canTable 1 Data on discordance of ER, PgR and HER2 status betw
Reference ER discordance (%)
Lindstrom et al. [7] 32.4
Niikura et al. [8] NR
Curigliano et al. [9] 15
Gong et al. [10] 7
Amir et al. [2] 12.6
Bogina et al. [11] 6
Wilking et al. [12] NR
Aitken et al. [13] 28
Amir et al. [4] 16
Idirisinghe et al. [14] 16
Simmons et al. [15] 40
Liedtke et al. [16] 18
Lower et al. [17] NR
Broom et al. [18] 17.7
Santinelli et al. [19] NR
Tapia et al. [20] NR
Lower et al. [21] 30
Carlsson et al. [22] NR
Edgerton et al. [23] NR
Gancberg et al. [24] NR
Simon et al. [25] NR
Mobbs et al. [26] 14
Guarneri et al. [27] 22
Hoefnagel et al. [28] 10.3
Thompson et al. [5] 10.2
Brogi et al. [29] 16.2
Chang et al. [30] 25
ER, estrogen receptor; HER, human epidermal growth factor receptor; NR, not reporestablish a diagnosis in patients with a single metastasis
who were until that time not known to have advanced
disease. Biopsies of suspected metastatic lesions can also
reveal an unsuspected non-malignant process or other
primary cancer. Quite recently, two independent, prospect-
ive studies reported on the clinical impact of biopsy of re-
current lesions [4,5]. The single-centre Canadian DESTINY
study and the multicentre UK Breast Recurrence In Tissues
Study (BRITS) revealed non-malignant processes in 3 out of
121 (2.5%) and in 18 out of 205 (8.8%) patients with
suspected metastases, respectively [4,5]. One woman who
participated in the DESTINY study had a second malig-
nancy (0.8%) [4]. Last but not least, biopsies can corroborate
or refute expression of breast cancer-related biomarkers
that influence treatment choice.
One of the main reasons supporting the need for biop-
sies of breast cancer metastases lies in the fact that
tissue sampling may be helpful in individualizing therapyeen primary and metastatic breast cancer
PgR discordance (%) HER2 discordance (%)
40.7 14.5
NR 43
49 14
NR NR
31.2 5.5
21 1
NR 10
23 9
40.4 9.6
38 5
40 8
40 14
NR 33
37.3 5.5
NR 18.9
NR 8
39 NR
NR 0
NR 15
NR 9
NR 3
28 NR
36 16
30 5.2
24.8 2.9
20.6 5
NR 12.5
ted; PgR, progesterone receptor.
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the primary tumor. The discordance in ER, PgR and
HER2 receptor status between primary and metastatic
breast cancer has been constantly reported [1] (Table 1).
This evidence has been mostly derived from retrospective
analyses investigating ER, PgR and HER2 status in hetero-
geneous sites of relapse [1]. Recently, a meta-analysis
showed that the rates of discordance for ER, PgR and
HER2 status were 20%, 33% and 8%, respectively [6].
Two alternative explanations may justify this observa-
tion: technical issues, including poor reproducibility of the
immunohistochemical technique, or actual tumor hetero-
geneity. The lack of perfect reproducibility in the assess-
ment of ER, PgR and HER2 status has been described in
prospective trials based on central pathology review
[31,32], and a mathematical model has been proposed
foreseeing a discordance rate of at least 10% even using an
ideal test yielding 95% accuracy, sensitivity and specificity,
a scenario reasonably far from clinical practice, where
additional variables may further affect reproducibility [33].
Very likely the technical issue on its own does not
completely explain the discrepancy in ER, PgR and HER2
status between primary tumors and relapses, as we would
likely observe roughly the same discordance rates for ER,
PgR and HER2 status, which is not the case [6]. Moreover,
the conversion to negative receptor status is, on average,
higher than the positive conversion (24% versus 14% for
ER, 46% versus 15% for PgR, and 13% versus 5% for
HER2); these would be expected to be similar if occurring
by chance or for technical reasons [6]. This observation
might be explained by the occurrence of mechanisms of
resistance, perhaps as the result of selection fostering ER-,
PgR- and HER2-negative tumor clones in the metastases.
On the other hand, recent studies based on next-
generation sequencing have shed new light on tumor
heterogeneity, reinforcing the hypothesis that variation in
ER, PgR and HER2 status may actually reflect clonal gen-
ome evolution. Tumor heterogeneity may be attributable
to tumor biological drift, selective pressures of therapy
leading to clonal selection with development of a novel
tumor cell clone, or presence of small subclones routinely
undetected within the primary tumor [3].
In the era of personalized medicine, biopsies may also
improve selection of patients for targeted therapy trials.
There is a considerable lack of understanding of metasta-
sis biology due to the imbalance between the abundance
of tissue from primary tumors and no cultures of metasta-
sis biopsies. This has led to the assumption that lessons
from primary breast cancer extend to metastatic breast
cancer. Despite the large number of papers published on
the role of genome sequencing in breast cancer, just two
[34,35] have focused on the metastatic site, while all the
others have focused on primary breast cancer. Commu-
nally, 900 primary breast cancers have been sequencedversus 10 breast cancer metastases. The characterization
of metastatic breast cancer has been systematically
neglected because of the difficulties culturing metastasis
biopsies. Hence, it is important to change attitudes in
order to better understand how metastases determine
outcome in breast cancer. Potentially, we can detect sub-
stantial genomic evolution between a primary tumor and
its metastases. All existing methods of classifying breast
cancer are predicated on primary breast cancer. However,
many metastatic-specific mutations do exist, many of
which may be driver mutations that could be targeted by
drugs, but unless biopsy of metastasis is performed we will
not be able to identify these relevant molecular targets.
Safety of the procedure and logistical
considerations
Biopsy cannot always be performed safely for the patient.
Generally, biopsy of metastases in patients with breast
cancer is carried out by percutaneous image-guided
biopsy, which is safe, effective, and is associated with min-
imal complications and patient discomfort. The Society of
Interventional Radiology reports a threshold of 2% for
major complications [36]. Generic complications include
bleeding, infection, perforation, and unintended organ
injury. Moreover, organ-specific complications associated
with biopsy can occur, such as hematuria with kidney
biopsy or pneumothorax with lung biopsy. Tumor seeding
after biopsy is very rare [37]. At the 2013 ASCO annual
meeting, Dr André reported that biopsy was complicated
by a serious adverse event in 9 out of 423 patients within
the SAFIR01 trial [38]. The acceptance, feasibility and
safety of sequential biopsies have been studied in the field
of clinical trials [39]. Additionally, iterative biopsies may
lead to delay in treatment in patients with metastatic
breast cancer [4]. Finally, it has to be acknowledged that
this procedure is financially expensive.
Treatment changes according to biopsy of the
metastasis
Few studies have reported treatment changes based on ana-
lysis of metastases (Table 2). In a pooled analysis of the pro-
spective BRITS and DESTINY studies, biopsy results
altered management in 14.2% of cases but the clinical
impact is unknown [2]. Modification of therapy was more
common when there was gain of receptor expression. Gain
of HER2 amplification resulted in a change of therapy in 11
patients, and gain of hormone receptor expression resulted
in a change of therapy in 9 patients. Loss of HER2 amplifi-
cation led to a change in therapy in 1 patient, and loss of
hormone receptor expression led to a change of therapy in
11 patients [2]. Overall, biomarker evaluation of metastasis
within prospective clinical trials led to therapeutic changes
in 17 to 20% of patients [4,5,15]. Loss or gain of biomarker
expression between primary tumor and metastasis may not
Table 2 Change in management based on biopsy
Reference Number of patients Therapy changed (%)
Lindstrom et al. [7] 1,010 23 (HER2) 50 (ER)
Curigliano et al. [9] 255 12.1
Amir et al. [2] 289 14.2
Bogina et al. [11] 140 7.3
Amir et al. [4] 121 14
Simmons et al. [15] 40 20
Thompson et al. [5] 137 17.5
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2.
Criscitiello et al. Breast Cancer Research Page 4 of 82014, 16:205
http://breast-cancer-research.com/content/16/2/205have the same therapeutic impact. Changing therapy based
on loss of a biomarker could avoid the prescription of an
unnecessary treatment with potential toxicity for the
patient, but data are not robust enough to affirm that an
agent should be discontinued based on a new biopsy of the
metastasis. Conversely, gain of a biomarker could offer the
possibility to adopt new therapies but this event is relatively
rare. Importantly, we have to highlight that the impact on
survival of biopsy-driven treatment has not been reported
to date in a prospective randomized trial.
Which metastasis to biopsy and when?
Breast cancer metastases have been poorly studied sys-
tematically, with usually only one of a breast cancer
patient's metastases biopsied with small tissue sample
(s). Whether the capacity to metastasize is an intrinsic
property of the tumor or an acquired feature, and
whether all cells in a primary tumor are capable of me-
tastasis or just a small subset (subclone) are unknown. It
is debatable whether different metastases in the same
patient are biologically different, perhaps as a result of
selection pressures. To address this issue, autopsy data
prospectively comparing primary tumor to paired mul-
tiple metastatic sites from eight patients found notice-
able similarities in terms of gene expression profiles,
suggesting that metastatic capability was an intrinsic
property of the primary tumor and not based on clonal
selection [40]. Another study compared the expression
of biomarkers between primary tumors and their paired
metastases and among different metastases from the
same patient; this study used archived primary breast
cancer and multiple different metastases collected at
autopsy from 10 consenting patients [41]. It revealed
consistency in ER, PgR and HER2 expression in different
metastases even if this was different to the expression in
the synchronous primary cancer [41].
Even assuming clinical and genomic heterogeneity
across metastases [3], we cannot sample all lesions,
clones or genomes in a single patient, as the cost-benefit
ratio would be too high. When proposing a biopsy to a
patient, we need to consider patient risk, inconvenience
and discomfort, although it has been reported that 51%of patients would altruistically consider having biopsies
for research purposes only with no clinical implications,
even knowing the risks, and 72% would consider having
additional biopsies to provide more material for research
[42]. Also, there are fiscal implications related to sam-
pling and analysis, although the economic burden of
metastatic breast cancer is overall remarkable in terms
of monetary cost [43].
Pragmatically, a valid strategy could consist of biopsy-
ing and analyzing the first metastasis and, accordingly,
selecting the subsequent treatment. Thereafter, for re-
sistant or relapsing lesions, further biopsy may be con-
sidered. Where cancer cells cannot be eliminated with a
single course of therapy, several steps may be required
considering individual clones and subclones within the
tumor. The timing of tumor reappearance should also
be considered as a variable to support biopsy of metasta-
sis. For late recurrences of ER + breast cancers, the
‘tumor dormancy’ scenario, there is a medical need for
confirmatory biopsy to ascertain histology.
Acquired resistance and biopsy of metastases
Treatment exposure may change the molecular profile of a
tumor and this can be assessed by performing biopsy of the
metastatic site. Challenges to targeted therapies include
acquired and primary resistance. Acquired resistance may
develop in most patients with metastatic breast cancer [44].
Some mechanisms by which a tumor stops responding to a
given therapy that it had initially responded to have been
identified in HER2+ tumors. These include loss of expres-
sion of the target as a result of continuous therapy [45],
activation of mutations downstream of the target itself, and
activation of additional mechanisms that promote cell
proliferation [46]. Primary resistance may occur due to lack
of target dependency. Furthermore, activation of compen-
satory pathways may rescue cells from the inhibitory effects
of blocking just one target or pathway.
While treatment of HER2+ breast cancer with the HER2-
targeted monoclonal antibody trastuzumab has demon-
strated significant improvements in patient outcome, nearly
70% of patients with HER2+ breast cancer demonstrate
resistance to trastuzumab in the metastatic setting [47-49].
Several mechanisms have been implicated in resistance to
trastuzumab, including increased signaling mediated by
growth factor receptors, alterations of the HER2 receptor,
phosphatase and tensin homolog (PTEN) loss, and aberrant
activity of the phosphatidylinositide 3-kinase (PI3K)/
mammalian target of rapamycin (mTOR) pathway. Quite
recently, contrary to some preclinical and a few clinical
studies suggesting a decrease in trastuzumab sensitivity in
patients with PTEN- tumors, Perez and colleagues [50]
showed that HER2+ breast cancer patients benefit from
adjuvant trastuzumab regardless of tumor PTEN status.
Therefore, inhibition of the PI3K/Akt/mTOR pathway with
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able approach to overcome resistance and restore sensitivity
to trastuzumab-based therapy. This hypothesis is supported
by preclinical studies in which PI3K inhibitors overcame
PTEN loss-induced trastuzumab resistance and slowed the
growth of HER2+ breast cancer cells in vitro and in vivo
[51,52]. Such a therapeutic approach has been adopted in
the BOLERO-3 (Breast Cancer Trials of Oral Everolimus)
clinical trial, in which the addition of everolimus to trastu-
zumab and vinorelbine significantly prolonged progression-
free survival in patients with HER2+ metastatic breast can-
cer resistant to trastuzumab, as presented by Dr O’Regan
during the 2013 ASCO annual meeting (unpublished obser-
vations, Ruth O’Regan).
Similarly, mutation frequencies in the ER gene (ESR1)
differ between primary and metastatic tumors, as seen
through large-scale next-generation sequencing of postmen-
opausal women with ER +metastatic breast cancer treated
with everolimus in combination with exemestane within the
BOLERO-2 trial, as presented by Dr Piccart at the 2013
IMPAKT meeting (unpublished observations, Martine
Piccart). The BOLERO-2-based dataset indicated enrich-
ment in ESR1 gene mutations from primary tumor samples
(7%) compared with metastatic tumor samples (19%). These
mutations appear to cluster in the ligand-binding domain,
so are probably affecting the binding of estrogen, rendering
these tumors likely estrogen-independent.
In such a context, the role of biopsy is crucial to develop
drugs that aim at reversing resistance, based on protein
assessment of the metastasis. This concept is in contrast
to the current concept of ‘oncogene de-addiction’, accord-
ing to which the oncogenic targets need to be present on
the primary tumor. Thus, on one hand the biopsy of the
primary tumor may be helpful to develop therapies that
aim to de-addict to oncogenes, and on the other biopsy of
metastases may be helpful to develop drugs that aim at
reversing resistance.
The role of biopsy for research purposes
Current molecular oncology technology enables us to
characterize the complete mutational landscape of cancers
[53,54]. This holds great promise with regard to under-
standing driving genetic aberrations, discovering new
therapeutic targets, elucidating tumor genetic heterogen-
eity and ultimately improving outcomes for cancer
patients. Recent studies using massively parallel sequen-
cing have uncovered a large number of potential ‘driver’
mutations that occur at a low frequency but are poten-
tially targetable by agents that are currently available for
other clinical indications or for possible breast cancer
clinical trials [53,54].
Breast cancer metastases often acquire new molecular
aberrations, and different treatment-resistant clones may
emerge over time. While the clinical relevance of thesephenomena is not yet well understood, it suggests that
metastatic lesions should be biopsied to recover the
genomic portrait of advanced breast cancers, and that
treatment decisions could conceivably be based on these
molecular profiles, rather than those of the primary
tumors. To this end, the Breast International Group (BIG)
is constructing a molecular screening program called
PRISM-BC that will facilitate the large-scale screening and
sequencing of metastatic breast cancer patients, using
metastatic biopsies, to determine which patients would be
eligible for phase II downstream therapeutic clinical trials
conducted under the BIG umbrella using novel targeted
agents. In this context, the French SAFIR02 program
(NCT01414933) aims at demonstrating the medical bene-
fits of treatment based on genomic analysis. Only a small
proportion of these patients will be identified with puta-
tive ‘actionable’ mutations, with the vast majority having
‘non-actionable’ mutations; BIG is committed to building
an important research program based on the follow-up of
screened but trial-ineligible patients to advance our know-
ledge of metastatic breast cancer.
The liquid biopsy
Tumors are heterogeneous and continuously evolve.
Evolutionary changes within the cancer can alter the
mutational spectrum of the disease and the responsive-
ness of the cancer to therapies. This may necessitate
repeat biopsies [55]. However, repeat biopsies are diffi-
cult, invasive, costly and somewhat limited in that they
provide a picture of mutations present only at a given
time and organ site [55]. Recent studies have shown that
genomic alterations in solid cancers can be characterized
by massively parallel sequencing of circulating cell-free
tumor DNA released from cancer cells into plasma,
representing a non-invasive liquid biopsy. For some
applications, mutation detection in plasma DNA could
potentially replace invasive biopsies as a means to assess
tumor genetic characteristics [55].
Genome-wide sequencing of plasma samples demon-
strates comprehensive coverage of the genome [56]. More
recently, genome-wide sequencing of plasma DNA has
been demonstrated as a potential tool for detection of
disease or analysis of tumor burden in patients with ad-
vanced cancers [55,57]. These studies have established
that plasma DNA can represent the entire tumor genome
[57]. However, identifying somatic mutations in cell-free
tumor DNA is expensive and technically challenging.
Analysis of isolated circulating tumor cells (CTCs) has
also been proposed. Characterization of CTCs could be
used to predict treatment response and personalize cancer
treatments [58]. However, isolation and characterization
of CTCs is expensive and technically demanding [58].
Moreover, CTCs are not always present and may repre-
sent a different fraction of cells from the bulk metastatic
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ing alternative to biopsies of metastatic lesions, we do not
yet consider circulating DNA or CTCs as the solution to
all our needs. Such an approach is useful for genomics,
but does not inform on in situ transcriptome, proteome,
lymphocytic infiltration or microenvironmental cues.
Conclusion
The well-documented heterogeneity in the primary
tumor supports the need for biopsy of one or more me-
tastases. While biopsy of the metastatic site may not be
prospectively able to demonstrate improved outcome for
each patient - at least for the time being - it is para-
mount to introduce a culture of systematically biopsying
metastases in order to gain information on the biology
of the disease and, accordingly, select the best treatment
option for our patients. This attitude is being introduced
at present in clinical trials and may in future become
standard clinical practice.
Hopefully, application of improved technology will ul-
timately translate into improved outcome. In this sce-
nario, biomarker-driven clinical trials with targeted
agents for patients with metastatic breast cancer with
relatively rare but ‘actionable’ mutations may became
crucial and biopsy of the metastatic tissues will be essen-
tial. We expect that future clinical trials will increasingly
require metastatic tissue to be obtained to assess mo-
lecular differences, not only at the receptor level but also
at the DNA, RNA, protein, and functional pathway
levels. Most current target-driven therapeutic interven-
tional trials will be developed according to a specific
molecular profile.
The metastases could also be biopsied soon after initi-
ation of treatment to determine by pharmacodynamic
endpoints whether the disease is responding and
whether treatment should be continued or discontinued
or additional treatments should be added. At disease
progression, biopsy of metastatic sites will be performed
to elucidate the molecular changes contributing to treat-
ment resistance, which may help to determine the next
treatment choices.
Routine sampling of metastatic tissue will give us the
opportunity to establish bio-banks of biopsy material
taken from metastatic sites. Such biobanks will be im-
portant for exploring mechanisms of metastasis. In the
future, advances in targeted therapy will depend on the
availability of such metastatic tissue. We need to ad-
vance translational research by using analysis of meta-
static tissue to design appropriate targeted therapy for
patients with metastatic disease and ultimately for pa-
tient benefit.
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